Nuvaxovid Jn.1

Matrix M, the active ingredient in Nuvaxovid Jn.1, is a recombinant protein subunit vaccine presented as a 0.5 mL dose for intramuscular use. It targets the SARS‑CoV‑2 Omicron JN.1 variant spike protein to stimulate protective immunity in adults.

GNH USA supplies Nuvaxovid Jn.1 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Nuvaxovid Jn.1 is designed to induce immunity against the SARS‑CoV‑2 Omicron JN.1 variant and is indicated for: - Primary vaccination: Provides protective immunity in individuals not previously vaccinated against COVID‑19. - Booster vaccination: Enhances immune response in persons who have completed a primary COVID‑19 vaccine series. - Heterologous boosting: Can be used to boost immunity after a primary series with a different COVID‑19 vaccine platform.

Adverse reactions reported with Nuvaxovid Jn.1 are generally mild to moderate and resolve without medical intervention.

Common Side Effects: - Injection site pain: mild discomfort at the injection site. - Fatigue: transient feeling of tiredness. - Headache: mild to moderate headache. - Myalgia: muscle aches. - Fever: low‑grade temperature elevation. - Nausea: occasional feeling of queasiness.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical care. - Guillain‑Barré syndrome: rare neurological disorder. - Thrombosis with thrombocytopenia: uncommon clotting event. - Myocarditis/pericarditis: inflammation of heart muscle or surrounding tissue. - Severe allergic reactions: including angio‑edema. - Immune‑mediated disorders: such as vasculitis.

Before administering Nuvaxovid Jn.1, consider the following precautions: - Contraindication: If the re‑    ... -  ...  .... ... ...  ...  ....  ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... … ... ... ... ... ... .... ... ... ... ... ... ... .... …  -  … … … ... ... ... ...

...